467 related articles for article (PubMed ID: 29533787)
1. Loss of KDM6A Activates Super-Enhancers to Induce Gender-Specific Squamous-like Pancreatic Cancer and Confers Sensitivity to BET Inhibitors.
Andricovich J; Perkail S; Kai Y; Casasanta N; Peng W; Tzatsos A
Cancer Cell; 2018 Mar; 33(3):512-526.e8. PubMed ID: 29533787
[TBL] [Abstract][Full Text] [Related]
2. Loss of KDM6A characterizes a poor prognostic subtype of human pancreatic cancer and potentiates HDAC inhibitor lethality.
Watanabe S; Shimada S; Akiyama Y; Ishikawa Y; Ogura T; Ogawa K; Ono H; Mitsunori Y; Ban D; Kudo A; Yamaoka S; Tanabe M; Tanaka S
Int J Cancer; 2019 Jul; 145(1):192-205. PubMed ID: 30556125
[TBL] [Abstract][Full Text] [Related]
3. Lysine Demethylase KDM6A in Differentiation, Development, and Cancer.
Tran N; Broun A; Ge K
Mol Cell Biol; 2020 Sep; 40(20):. PubMed ID: 32817139
[TBL] [Abstract][Full Text] [Related]
4. Lysine demethylases KDM6A and UTY: The X and Y of histone demethylation.
Gažová I; Lengeling A; Summers KM
Mol Genet Metab; 2019 May; 127(1):31-44. PubMed ID: 31097364
[TBL] [Abstract][Full Text] [Related]
5. DeltaNp63-dependent super enhancers define molecular identity in pancreatic cancer by an interconnected transcription factor network.
Hamdan FH; Johnsen SA
Proc Natl Acad Sci U S A; 2018 Dec; 115(52):E12343-E12352. PubMed ID: 30541891
[TBL] [Abstract][Full Text] [Related]
6. UTX/KDM6A Loss Enhances the Malignant Phenotype of Multiple Myeloma and Sensitizes Cells to EZH2 inhibition.
Ezponda T; Dupéré-Richer D; Will CM; Small EC; Varghese N; Patel T; Nabet B; Popovic R; Oyer J; Bulic M; Zheng Y; Huang X; Shah MY; Maji S; Riva A; Occhionorelli M; Tonon G; Kelleher N; Keats J; Licht JD
Cell Rep; 2017 Oct; 21(3):628-640. PubMed ID: 29045832
[TBL] [Abstract][Full Text] [Related]
7. HNF1A recruits KDM6A to activate differentiated acinar cell programs that suppress pancreatic cancer.
Kalisz M; Bernardo E; Beucher A; Maestro MA; Del Pozo N; Millán I; Haeberle L; Schlensog M; Safi SA; Knoefel WT; Grau V; de Vas M; Shpargel KB; Vaquero E; Magnuson T; Ortega S; Esposito I; Real FX; Ferrer J
EMBO J; 2020 May; 39(9):e102808. PubMed ID: 32154941
[TBL] [Abstract][Full Text] [Related]
8. Disruption of BRD4 at H3K27Ac-enriched enhancer region correlates with decreased c-Myc expression in Merkel cell carcinoma.
Sengupta D; Kannan A; Kern M; Moreno MA; Vural E; Stack B; Suen JY; Tackett AJ; Gao L
Epigenetics; 2015; 10(6):460-6. PubMed ID: 25941994
[TBL] [Abstract][Full Text] [Related]
9. X chromosome protects against bladder cancer in females via a
Kaneko S; Li X
Sci Adv; 2018 Jun; 4(6):eaar5598. PubMed ID: 29928692
[TBL] [Abstract][Full Text] [Related]
10. Unveiling the Molecular Landscape of Pancreatic Ductal Adenocarcinoma: Insights into the Role of the COMPASS-like Complex.
Jamali M; Barar E; Shi J
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791111
[TBL] [Abstract][Full Text] [Related]
11. Histone H3K27 demethylase KDM6A is an epigenetic gatekeeper of mTORC1 signalling in cancer.
Revia S; Seretny A; Wendler L; Banito A; Eckert C; Breuer K; Mayakonda A; Lutsik P; Evert M; Ribback S; Gallage S; Chikh Bakri I; Breuhahn K; Schirmacher P; Heinrich S; Gaida MM; Heikenwälder M; Calvisi DF; Plass C; Lowe SW; Tschaharganeh DF
Gut; 2022 Aug; 71(8):1613-1628. PubMed ID: 34509979
[TBL] [Abstract][Full Text] [Related]
12. The histone demethylase UTX/KDM6A in cancer: Progress and puzzles.
Schulz WA; Lang A; Koch J; Greife A
Int J Cancer; 2019 Aug; 145(3):614-620. PubMed ID: 30628063
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic regulation of epithelial-mesenchymal transition by KDM6A histone demethylase in lung cancer cells.
Terashima M; Ishimura A; Wanna-Udom S; Suzuki T
Biochem Biophys Res Commun; 2017 Sep; 490(4):1407-1413. PubMed ID: 28698146
[TBL] [Abstract][Full Text] [Related]
14. DISORDERED HISTONE METHYLATION IN HEMATOLOGICAL MALIGNANCIES THE CASE OF UTX/KDM6A.
Licht JD
Trans Am Clin Climatol Assoc; 2018; 129():24-36. PubMed ID: 30166694
[TBL] [Abstract][Full Text] [Related]
15. FBP1 loss contributes to BET inhibitors resistance by undermining c-Myc expression in pancreatic ductal adenocarcinoma.
Wang B; Fan P; Zhao J; Wu H; Jin X; Wu H
J Exp Clin Cancer Res; 2018 Sep; 37(1):224. PubMed ID: 30201002
[TBL] [Abstract][Full Text] [Related]
16. KMT2D Deficiency Impairs Super-Enhancers to Confer a Glycolytic Vulnerability in Lung Cancer.
Alam H; Tang M; Maitituoheti M; Dhar SS; Kumar M; Han CY; Ambati CR; Amin SB; Gu B; Chen TY; Lin YH; Chen J; Muller FL; Putluri N; Flores ER; DeMayo FJ; Baseler L; Rai K; Lee MG
Cancer Cell; 2020 Apr; 37(4):599-617.e7. PubMed ID: 32243837
[TBL] [Abstract][Full Text] [Related]
17. Loss of histone demethylase KDM6B enhances aggressiveness of pancreatic cancer through downregulation of C/EBPα.
Yamamoto K; Tateishi K; Kudo Y; Sato T; Yamamoto S; Miyabayashi K; Matsusaka K; Asaoka Y; Ijichi H; Hirata Y; Otsuka M; Nakai Y; Isayama H; Ikenoue T; Kurokawa M; Fukayama M; Kokudo N; Omata M; Koike K
Carcinogenesis; 2014 Nov; 35(11):2404-14. PubMed ID: 24947179
[TBL] [Abstract][Full Text] [Related]
18. KDM6A Loss Recruits Tumor-Associated Neutrophils and Promotes Neutrophil Extracellular Trap Formation in Pancreatic Cancer.
Yang J; Jin L; Kim HS; Tian F; Yi Z; Bedi K; Ljungman M; Pasca di Magliano M; Crawford H; Shi J
Cancer Res; 2022 Nov; 82(22):4247-4260. PubMed ID: 36306422
[TBL] [Abstract][Full Text] [Related]
19. Lysine-specific Demethylase 6A Upregulates Cadherin-1 and Accelerates Gastric Cancer Growth.
Li D; Zhang S; Yan Q; Li Y
Curr Pharm Biotechnol; 2023; 24(14):1827-1835. PubMed ID: 36941815
[TBL] [Abstract][Full Text] [Related]
20. Inherited KDM6A
Feng M; Chai C; Hao X; Lai X; Luo Y; Zhang H; Tang W; Gao N; Pan G; Liu X; Wang Y; Xiong W; Wu Q; Wang J
Oncogene; 2024 Jun; 43(23):1757-1768. PubMed ID: 38622203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
